EU Approves Kimberly-Clark’s US$40 Billion Kenvue Acquisition Following Divestment Agreement

Kimberly-Clark (KMB) received EU approval to acquire Kenvue, a consumer health company, with conditions requiring divestitures. The deal is subject to regulatory approval in other jurisdictions. KMB's stock is currently trading at $98.29 USD, with a 5-day change of -0.49%.

The European Commission approved Kimberly-Clark's acquisition of Kenvue, conditional on divesting tampon brands in the EEA. Concerns were raised about reduced competition in Czechia, Estonia, and Slovakia. Dilek Gıda was approved as the purchaser of the divested business. The decision is subject to full compliance with commitments.

The European Commission approved Kimberly-Clark's $40 billion acquisition of Kenvue, requiring the sale of certain tampon brands. The deal is subject to divestitures to address competition concerns. Kimberly-Clark's stock has seen recent fluctuations, with a 5-day change of -0.49%.

The EU approved Kimberly-Clark's $40B acquisition of Kenvue, requiring divestment of Kotex, Camelia, and Record brands in the EEA to Dilek. The Commission cited competition concerns in Czechia, Estonia, and Slovakia. Dilek was approved as the buyer, with an independent trustee to monitor compliance. The deal was notified on 25 August 2026.

Kimberly-Clark's $40B acquisition of Kenvue received conditional EU approval. The deal requires selling feminine hygiene brands in Europe, addressing competition concerns in Czech Republic, Estonia, and Slovakia. Turkey's Dilek Gida Uretim will acquire the divested brands.

Kimberly-Clark's $48.7bn acquisition of Kenvue has been approved by the EU, contingent on divesting its tampon and feminine hygiene business in the European Economic Area. The EU cited competition concerns in several countries.